Home Cart Sign in  
Chemical Structure| 1215011-08-7 Chemical Structure| 1215011-08-7

Structure of PCLX-001
CAS No.: 1215011-08-7

Chemical Structure| 1215011-08-7

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

PCLX-001 is an orally active N-methyltransferase inhibitor with significant antitumor activity, capable of inhibiting early B cell receptor signaling, showing potential in malignant lymphoma research.

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of PCLX-001

CAS No. :1215011-08-7
Formula : C24H30Cl2N6O2S
M.W : 537.51
SMILES Code : O=S(C1=C(Cl)C=C(C2=CC(N3CCNCC3)=NC=C2)C=C1Cl)(NC4=C(C)N(C)N=C4CC(C)C)=O
MDL No. :N/A
InChI Key :WKTSLVQYGBHNRV-UHFFFAOYSA-N
Pubchem ID :58561243

Safety of PCLX-001

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319
Precautionary Statements:P501-P270-P264-P280-P302+P352-P337+P313-P305+P351+P338-P362+P364-P332+P313-P301+P312+P330

Isoform Comparison

Biological Activity

In Vitro:

Cell Line
Concentration Treated Time Description References
IM9 cells 0.01–1.0 µM 1 hour Inhibition of total protein myristoylation, higher concentrations of PCLX-001 are required Nat Commun. 2020 Oct 22;11(1):5348
BL2 cells 0.01–1.0 µM 1 hour Inhibition of total protein myristoylation, malignant BL2 cells are more sensitive to PCLX-001 inhibition Nat Commun. 2020 Oct 22;11(1):5348
COS-7 cells 1.0–10 µM 24 hours Inhibition of Src protein myristoylation, leading to its relocalization from plasma and endosomal membranes to the cytoplasm Nat Commun. 2020 Oct 22;11(1):5348
BL2 cells 2 to 20 nM 6 monthourss Selection of PCLX-001 resistant cells, results showed an approximately twofold increase in EC50 of resistant cells and a significant increase in NMT2 protein levels. J Transl Med. 2024 May 7;22(1):431
HAP1 cells 0.5 or 5 µM 72 hours Evaluate the impact of PCLX-001 on the proteome of HAP1 cells, results showed significant downregulation of mitochondrial respiratory complex I proteins. J Transl Med. 2024 May 7;22(1):431
MCF7 210 nM (IC50) 72 hours To determine the inhibitory effect of PCLX-001 on MCF7 cells, IC50 was 210 nM Breast Cancer Res Treat. 2021 Feb;186(1):79-87
Hs 578T 111 nM (IC50) 72 hours To determine the inhibitory effect of PCLX-001 on Hs 578T cells, IC50 was 111 nM Breast Cancer Res Treat. 2021 Feb;186(1):79-87
DU4475 636 nM (IC50) 72 hours To determine the inhibitory effect of PCLX-001 on DU4475 cells, IC50 was 636 nM Breast Cancer Res Treat. 2021 Feb;186(1):79-87
BT-549 130 nM (IC50) 72 hours To determine the inhibitory effect of PCLX-001 on BT-549 cells, IC50 was 130 nM Breast Cancer Res Treat. 2021 Feb;186(1):79-87
BT-20 28,446 nM (IC50) 72 hours To determine the inhibitory effect of PCLX-001 on BT-20 cells, IC50 was 28,446 nM Breast Cancer Res Treat. 2021 Feb;186(1):79-87
AU-565 193 nM (IC50) 72 hours To determine the inhibitory effect of PCLX-001 on AU-565 cells, IC50 was 193 nM Breast Cancer Res Treat. 2021 Feb;186(1):79-87
COS-7 cells 10 μM 24 hours PCLX-001 inhibits myristoylation of the WT-Src-EGFP construct and relocalizes its distribution pattern. Nat Commun. 2020 Oct 22;11(1):5348
IM9 cells 0.01–1.0 μM 1 hour PCLX-001 inhibits total protein myristoylation in IM9 cells in a concentration-dependent manner. Nat Commun. 2020 Oct 22;11(1):5348
BL2 cells 0.01–1.0 μM 1 hour PCLX-001 inhibits total protein myristoylation in BL2 cells in a concentration-dependent manner. Nat Commun. 2020 Oct 22;11(1):5348

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
Mice DOHH2 tumor xenograft model Subcutaneous injection 20 mg/kg or 50 mg/kg Daily or every other day for 7 days PCLX-001 significantly inhibits tumor growth, with 50 mg/kg daily dose reducing tumor volume by up to 70% Nat Commun. 2020 Oct 22;11(1):5348
NODscid mice MDA-MB-231 breast cancer xenograft model Oral 35 mg/kg and 50 mg/kg Once daily for 21 days To evaluate the inhibitory effect of PCLX-001 on MDA-MB-231 xenograft tumors, tumor growth inhibition was 55.7% in the 35 mg/kg group and 71.8% in the 50 mg/kg group Breast Cancer Res Treat. 2021 Feb;186(1):79-87
Mice DOHH2 and BL2 lymphoma xenograft models Subcutaneous injections 20–60 mg/kg Daily for 13–21 days PCLX-001 treatment significantly inhibits tumor growth and leads to 100% tumor regression in the BL2 xenograft model. Nat Commun. 2020 Oct 22;11(1):5348

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

1.86mL

0.37mL

0.19mL

9.30mL

1.86mL

0.93mL

18.60mL

3.72mL

1.86mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2
 

Historical Records

Categories